» Articles » PMID: 22856463

Effects of Intensified Conditioning on Epstein-Barr Virus and Cytomegalovirus Infections in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Overview
Journal J Hematol Oncol
Publisher Biomed Central
Specialties Hematology
Oncology
Date 2012 Aug 4
PMID 22856463
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Intensified conditioning regimens (increasing the intensity of standard myeloablative conditioning) for hematological malignancies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce the relapse rate of the underlying disease, but it might simultaneously increase the transplant-related mortality including the mortality of infections. To explore whether intensified conditioning affected Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, 185 patients undergoing allo-HSCT were enrolled.

Methods: A total of 104 cases received standard and 81 intensified conditioning. Cyclosporine A (CsA) withdrawal and/or donor lymphocyte infusion (DLI) were conducted in high-risk patients. The EBV-DNA and CMV-DNA levels of blood were monitored regularly by quantitative real-time polymerase chain reaction (RQ-PCR) and immune reconstitution of recipients were analyzed by flow cytometry.

Results: The 3-year cumulative incidence of EBV viremia, EBV-associated diseases and mortality of EBV-associated diseases were 25.3% ± 4.6%, 10.5% ± 3.4% and 0.0% ± 0.0% in the standard group, compared with 45.6% ± 6.5%, 26.0% ±5.3% and 7.3% ± 3.1% in the intensified group (P = 0.002, P = 0.002, P = 0.008). The 3-year cumulative incidence of CMV viremia and CMV-associated diseases, mortality of CMV-associated diseases and incidence of bacterial and fungal infections were similar between the two groups (P = 0.855, P = 0.581, P = 0.933, P = 0.142, P = 0.182, respectively). Multivariate analysis showed that intensified conditioning was one of the risk factors for EBV viremia and EBV-associated diseases (P = 0.037, P = 0.037), but it had no effects on CMV infections. The percentage of CD4+ T cells and CD4+/CD8+ ratio at 3 months post-transplantation were lower in the intensified group (P = 0.032, P = 0.022). The 3-year OS and DFS in the standard group were 62.2% ± 5.8% and 60.6% ± 5.6%, compared with 51.6% ± 6.2% and 51.1% ± 5.9% in the intensified group (P = 0.029, P = 0.063).

Conclusions: Intensified conditioning represents a promising approach for high-risk hematological malignancies, although it affects early immune reconstitution of recipients and increases the incidence and mortality of EBV infections.

Citing Articles

[Maribavir treatment for refractory and drug-intolerant cytomegalovirus viremia and disease after allogeneic hematopoietic stem cell transplantation: a clinical analysis of 25 cases].

Ma W, Wei Z, Lu Y, Zhang J, Sun R, Xiong M Zhonghua Xue Ye Xue Za Zhi. 2025; 45(11):1010-1015.

PMID: 39746694 PMC: 11886685. DOI: 10.3760/cma.j.cn121090-20240919-00355.


[Early cellular immune exhaustion in patients with Epstein-Barr virus activation following haploidentical hematopoietic stem cell transplantation].

Huang Y, Zhang S, He J, Zhou Y, Xue R, Fan Z Zhonghua Xue Ye Xue Za Zhi. 2025; 45(11):998-1004.

PMID: 39746692 PMC: 11886675. DOI: 10.3760/cma.j.cn121090-20240825-00322.


CD34+ cell dose and CMV viremia after haploidentical hematopoietic stem cell transplantation: a retrospective study.

Yan P, Pan X, Hao Q, Wang J Am J Transl Res. 2024; 16(9):5130-5136.

PMID: 39398542 PMC: 11470346. DOI: 10.62347/SOPM3064.


Epstein-Barr virus as a potentiator of autoimmune diseases.

Robinson W, Younis S, Love Z, Steinman L, Lanz T Nat Rev Rheumatol. 2024; 20(11):729-740.

PMID: 39390260 DOI: 10.1038/s41584-024-01167-9.


Cytomegalovirus results in poor graft function via bone marrow-derived endothelial progenitor cells.

Lv W, Zhou Y, Zhao K, Xuan L, Huang F, Fan Z Front Microbiol. 2024; 15:1463335.

PMID: 39360328 PMC: 11445044. DOI: 10.3389/fmicb.2024.1463335.


References
1.
Jaskula E, Dlubek D, Sedzimirska M, Duda D, Tarnowska A, Lange A . Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation. Transplant Proc. 2010; 42(8):3273-6. DOI: 10.1016/j.transproceed.2010.07.027. View

2.
Landgren O, Gilbert E, Rizzo J, Socie G, Banks P, Sobocinski K . Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009; 113(20):4992-5001. PMC: 2686146. DOI: 10.1182/blood-2008-09-178046. View

3.
Liu Y, Lu P, Hsiao H, Chang C, Liu T, Yang W . Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann Hematol. 2011; 91(4):587-95. DOI: 10.1007/s00277-011-1351-8. View

4.
Martin-Pena A, Aguilar-Guisado M, Espigado I, Parody R, Cisneros J . Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. Clin Transplant. 2010; 25(3):468-74. DOI: 10.1111/j.1399-0012.2010.01286.x. View

5.
Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C . Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica. 2002; 87(1):52-8. View